Insmed | INSM - Des Atouts





Des Atouts Changement Date
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Cytokinetics USD 1.42B 12.02M 2025-12
DBV Technologies USD 110.49M 32.93M 2025-09
Gilead Sciences USD 59.02B 490M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Insmed USD 2.26B 96.18M 2025-12
Novartis USD 107.29B 2.89B 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12